{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:28:56Z","timestamp":1764174536457,"version":"3.37.3"},"reference-count":22,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2018,5,8]],"date-time":"2018-05-08T00:00:00Z","timestamp":1525737600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006606","name":"Natural Science Foundation of Tianjin City","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Thoracic Cancer"],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:p>Thymic carcinoma (TC) is a rare malignant tumor of the mediastinum with occult onset, rapid development, and poor prognosis. Surgery is the main treatment for early TC, but the majority of patients are diagnosed at Masaoka\u2010Koga stage III or IV with local invasion or distant metastasis. Platinum and anthracyclines are currently considered key components of first\u2010line chemotherapy for advanced TC; however, there are no standard treatment plans for patients who are refractory to first\u2010line and further chemotherapy. The clinical effect is also unsatisfactory. Apatinib has been successfully applied as third\u2010line treatment for advanced gastric cancer and has shown high efficacy in the treatment of various cancers, such as lung, liver, and colorectal cancers. Herein we report a case of advanced thymic squamous cell carcinoma harboring <jats:italic>EGFR<\/jats:italic> exon 20 insertion in which apatinib was administered after multi\u2010line chemotherapy and radiotherapy and a partial response was achieved after five months of treatment. To date, a five month overall response and 10 months of progression\u2010free survival have been achieved. Adverse reactions can be controlled and the patient's quality of life has improved. Apatinib provides a new option for clinicians to treat patients with advanced TC.<\/jats:p>","DOI":"10.1111\/1759-7714.12755","type":"journal-article","created":{"date-parts":[[2018,5,9]],"date-time":"2018-05-09T05:53:10Z","timestamp":1525845190000},"page":"885-891","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["<scp><i>EGFR<\/i><\/scp> exon 20 insertion mutation in advanced thymic squamous cell carcinoma: <scp>R<\/scp>esponse to apatinib and clinical outcomes"],"prefix":"10.1111","volume":"9","author":[{"given":"Su","family":"Yudong","sequence":"first","affiliation":[{"name":"Tianjin Tumor Hospital  Tianjin China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Zhaoting","sequence":"additional","affiliation":[{"name":"Tianjin Tumor Hospital  Tianjin China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang","family":"Xinyue","sequence":"additional","affiliation":[{"name":"Tianjin Tumor Hospital  Tianjin China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[{"name":"Tianjin Tumor Hospital  Tianjin China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Xiaoyan","sequence":"additional","affiliation":[{"name":"Tianjin Tumor Hospital  Tianjin China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuo","family":"Ran","sequence":"additional","affiliation":[{"name":"Tianjin Tumor Hospital  Tianjin China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Jinliang","sequence":"additional","affiliation":[{"name":"Tianjin Tumor Hospital  Tianjin China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4108-5915","authenticated-orcid":false,"given":"Chen","family":"Peng","sequence":"additional","affiliation":[{"name":"Tianjin Tumor Hospital  Tianjin China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,5,8]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.02.047"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181f1f62d"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1309\/AJCP88FZTWANLRCB"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2007.11.004"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.3960\/jslrt.53.9"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01088-0"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20110301"},{"key":"e_1_2_6_9_1","first-page":"Abstract 1764","article-title":"VEGFR inhibitor YN968D1 xenograft dose response studies against human colon cancer Ls174t and HT29","volume":"47","author":"Chen P","year":"2006","journal-title":"Proc Am Assoc Cancer Res"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-013-3452-1"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1604958"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2009.03.033"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2016.01.79"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-014-1800-6"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2014.11.006"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181f209b9"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2006.01.009"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.18316"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30062-7"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2015.05.011"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aanat.2007.05.003"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtbi.2012.12.013"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.5995"}],"container-title":["Thoracic Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1759-7714.12755","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.12755","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T07:11:52Z","timestamp":1694848312000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1759-7714.12755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,8]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["10.1111\/1759-7714.12755"],"URL":"https:\/\/doi.org\/10.1111\/1759-7714.12755","archive":["Portico"],"relation":{},"ISSN":["1759-7706","1759-7714"],"issn-type":[{"type":"print","value":"1759-7706"},{"type":"electronic","value":"1759-7714"}],"subject":[],"published":{"date-parts":[[2018,5,8]]},"assertion":[{"value":"2018-03-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}